/ /

  • linkedin
  • Increase Font
  • Sharebar

    10 things you may have missed at ARVO

    1. Emerging drug targets waste build-up in Stargardt disease


    A new drug (ALK-001, Alkeus) has been reported as safe in a 4-week, phase I safety-only study for preventing the formation of toxic waste in the macula. Researchers hope to learn more about the drug’s capabilities to slow vision loss and potentially explore if the agent can also be used in other macular diseases, such as dry AMD.


    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results